GLP1 Agonist Exposure in Pregnancy
Dr. Chapa’s Clinical Pearls.
English - March 05, 2024 02:04 - 40 minutes - 36.8 MB - ★★★★★ - 252 ratingsScience Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Foley For CX: Tension or No Tension? And More (March 2024 Data)
Next Episode: OPill…Now HERE! (ACOG PA March 2024)
Use of second-line noninsulin diabetic medications, like Glucagon-like peptide 1 (GLP-1) agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors, is rapidly increasing for treatment of T2D and other indications. As these drugs are being used by an increasing group of fertile women, it is expected that a few of them will get pregnant and data on their safety when used in the first trimester is needed. Is periconceptional use of glucagon-like peptide 1 (GLP-1) receptor agonists associated with increased risk of major congenital malformations? In this episode, we will look at the available data (although limited) regarding these medications, focusing on specific GLP1 options.